TY - JOUR
T1 - Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand
AU - Li, Yifan
AU - Merbah, Mélanie
AU - Wollen-Roberts, Suzanne
AU - Beckman, Bradley
AU - Mdluli, Thembi
AU - Swafford, Isabella
AU - Mayer, Sandra V.
AU - King, Jocelyn
AU - Corbitt, Courtney
AU - Currier, Jeffrey R.
AU - Liu, Heather
AU - Esber, Allahna
AU - Pinyakorn, Suteeraporn
AU - Parikh, Ajay
AU - Francisco, Leilani V.
AU - Phanuphak, Nittaya
AU - Maswai, Jonah
AU - Owuoth, John
AU - Kibuuka, Hannah
AU - Iroezindu, Michael
AU - Bahemana, Emmanuel
AU - Vasan, Sandhya
AU - Ake, Julie A.
AU - Modjarrad, Kayvon
AU - Gromowski, Gregory
AU - Paquin-Proulx, Dominic
AU - Rolland, Morgane
N1 - Funding Information:
This work was supported by a cooperative agreement (no. WW81XWH-18-2-0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the US Department of Defense. The RV254/ SEARCH 010 study was also supported by an intramural grant from the Thai Red Cross AIDS Research Centre and, in part, by the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institute of Health (grant no. AAI20052001). Antiretroviral therapy for RV254/SEARCH 010 participants was supported by the Thai Government Pharmaceutical Organization, Gilead Sciences, Merck, and ViiV Healthcare. RV329/AFRICOS study was supported by the US President’s Emergency Plan for AIDS Relief through DoD. The RV466/JWARG protocol is a multisite study under the Joint West Africa Research Group, which is supported, as a program of record, by the US Defense Health Agency in partnership with the Nigeria Ministry of Defence, Ghana Armed Forces, and the Armed Forces of Liberia. The AFRICOS study would not be possible without support from the hospital leadership at Kayunga District Hospital, Kericho District Hospital, AC Litein Mission Hospital, Kapkatet District Hospital, Tenwek Mission Hospital, Kapsabet District Hospital, Nandi Hills District Hospital, Kisumu West District Hospital, Mbeya Zonal Referral Hospital, Mbeya Regional Referral Hospital, Defence Headquarters Medical Center, and 68 Nigerian Army Reference Hospital.
Funding Information:
WW81XWH-18-2-0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the US Department of Defense. The RV254/ SEARCH 010 study was also supported by an intramural grant from the Thai Red Cross AIDS Research Centre and, in part, by the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institute of Health (grant no. AAI20052001). Antiretroviral therapy for RV254/SEARCH 010 participants was supported by the Thai Government Pharmaceutical Organization, Gilead Sciences, Merck, and ViiV Healthcare. RV329/AFRICOS study was supported by the US President’s Emergency Plan for AIDS Relief through DoD. The RV466/JWARG protocol is a multisite study under the Joint West Africa Research Group, which is supported, as a program of record, by the US Defense Health Agency in partnership with the Nigeria Ministry of Defence, Ghana Armed Forces, and the Armed Forces of Liberia. The AFRICOS study would not be possible without support from the hospital leadership at Kayunga District Hospital, Kericho District Hospital, AC Litein Mission Hospital, Kapkatet District Hospital, Tenwek Mission Hospital, Kapsabet District Hospital, Nandi Hills District Hospital, Kisumu West District Hospital, Mbeya Zonal Referral Hospital, Mbeya Regional Referral Hospital, Defence Headquarters Medical Center, and 68 Nigerian Army Reference Hospital.
Funding Information:
This work was supported by a cooperative agreement (no.
Publisher Copyright:
© 2022 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2022/11
Y1 - 2022/11
N2 - Prior immune responses to coronaviruses might affect human SARS-CoV-2 response. We screened 2,565 serum and plasma samples collected from 2013 through early 2020, before the COVID-19 pandemic began, from 2,250 persons in 4 countries in Africa (Kenya, Nigeria, Tanzania, and Uganda) and in Thailand, including persons living with HIV-1. We detected IgG responses to SARS-CoV-2 spike (S) subunit 2 protein in 1.8% of participants. Profiling against 23 coronavirus antigens revealed that responses to S, subunit 2, or subunit 1 proteins were significantly more frequent than responses to the receptor-binding domain, S-Trimer, or nucleocapsid proteins (p<0.0001). We observed similar responses in persons with or without HIV-1. Among all coronavirus antigens tested, SARS-CoV-2, SARS-CoV-1, and Middle East respiratory syndrome coronavirus antibody responses were much higher in participants from Africa than in participants from Thailand (p<0.01). We noted less pronounced differences for endemic coronaviruses. Serosurveys could affect vaccine and monoclonal antibody distribution across global populations.
AB - Prior immune responses to coronaviruses might affect human SARS-CoV-2 response. We screened 2,565 serum and plasma samples collected from 2013 through early 2020, before the COVID-19 pandemic began, from 2,250 persons in 4 countries in Africa (Kenya, Nigeria, Tanzania, and Uganda) and in Thailand, including persons living with HIV-1. We detected IgG responses to SARS-CoV-2 spike (S) subunit 2 protein in 1.8% of participants. Profiling against 23 coronavirus antigens revealed that responses to S, subunit 2, or subunit 1 proteins were significantly more frequent than responses to the receptor-binding domain, S-Trimer, or nucleocapsid proteins (p<0.0001). We observed similar responses in persons with or without HIV-1. Among all coronavirus antigens tested, SARS-CoV-2, SARS-CoV-1, and Middle East respiratory syndrome coronavirus antibody responses were much higher in participants from Africa than in participants from Thailand (p<0.01). We noted less pronounced differences for endemic coronaviruses. Serosurveys could affect vaccine and monoclonal antibody distribution across global populations.
UR - http://www.scopus.com/inward/record.url?scp=85140855226&partnerID=8YFLogxK
U2 - 10.3201/eid2811.221041
DO - 10.3201/eid2811.221041
M3 - Article
C2 - 36220131
AN - SCOPUS:85140855226
SN - 1080-6040
VL - 28
SP - 2214
EP - 2225
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 11
ER -